A number of research firms have changed their ratings and price targets for Cellebrite DI (NASDAQ: CLBT):
- 8/16/2024 – Cellebrite DI had its price target raised by analysts at Deutsche Bank Aktiengesellschaft from $15.00 to $18.00. They now have a “buy” rating on the stock.
- 8/16/2024 – Cellebrite DI had its price target raised by analysts at Bank of America Co. from $13.00 to $17.00. They now have a “buy” rating on the stock.
- 8/16/2024 – Cellebrite DI had its price target raised by analysts at Lake Street Capital from $13.50 to $17.00. They now have a “buy” rating on the stock.
- 8/16/2024 – Cellebrite DI had its price target raised by analysts at Craig Hallum from $16.00 to $20.00. They now have a “buy” rating on the stock.
- 8/16/2024 – Cellebrite DI had its price target raised by analysts at Needham & Company LLC from $14.00 to $17.00. They now have a “buy” rating on the stock.
- 8/14/2024 – Cellebrite DI had its price target raised by analysts at JPMorgan Chase & Co. from $14.00 to $15.00. They now have an “overweight” rating on the stock.
Cellebrite DI Stock Down 2.1 %
Shares of NASDAQ CLBT traded down $0.37 during mid-day trading on Wednesday, reaching $17.03. 739,609 shares of the company were exchanged, compared to its average volume of 1,142,971. The company’s 50 day moving average price is $13.32 and its 200 day moving average price is $11.95. The stock has a market capitalization of $3.51 billion, a PE ratio of -29.36, a PEG ratio of 1.75 and a beta of 1.50. Cellebrite DI Ltd. has a 52 week low of $6.36 and a 52 week high of $17.48.
Cellebrite DI (NASDAQ:CLBT – Get Free Report) last announced its quarterly earnings data on Thursday, August 15th. The company reported $0.10 EPS for the quarter, beating the consensus estimate of $0.08 by $0.02. The business had revenue of $95.70 million during the quarter, compared to analyst estimates of $91.94 million. Cellebrite DI had a positive return on equity of 5,902.06% and a negative net margin of 28.51%. The company’s revenue for the quarter was up 24.8% on a year-over-year basis. During the same quarter last year, the firm posted $0.05 earnings per share. On average, sell-side analysts predict that Cellebrite DI Ltd. will post 0.41 earnings per share for the current year.
Institutional Inflows and Outflows
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.
Read More
- Five stocks we like better than Cellebrite DI
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- BHP Stock: The Under-the-Radar Growth Story in Commodities
- What are earnings reports?
- Analysts Upgrade These 3 Hot Buy-and-Hold Stocks
- What Are Dividend Challengers?
- Kohl’s Charts a Resilient Path in a Challenging Retail Landscape
Receive News & Ratings for Cellebrite DI Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellebrite DI Ltd and related companies with MarketBeat.com's FREE daily email newsletter.